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Abstract
Last decade witnessed an enormous progress in generating authentic infectious prions or PrPSc in vitro using
recombinant prion protein (rPrP). Previous work established that rPrP that lacks posttranslational modification is able
to support replication of highly infectious PrPSc with assistance of cofactors of polyanionic nature and/or lipids.
Unexpectedly, previous studies also revealed that seeding of rPrP by brain-derived PrPSc gave rise to new prion
strains with new disease phenotypes documenting loss of a strain identity upon replication in rPrP substrate. Up to
now, it remains unclear whether prion strain identity can be preserved upon replication in rPrP. The current study
reports that faithful replication of hamster strain SSLOW could be achieved in vitro using rPrP as a substrate. We
found that a mixture of phosphatidylethanolamine (PE) and synthetic nucleic acid polyA was sufficient for stable
replication of hamster brain-derived SSLOW PrPSc in serial Protein Misfolding Cyclic Amplification (sPMCA) that uses
hamster rPrP as a substrate. The disease phenotype generated in hamsters upon transmission of recombinant PrPSc
produced in vitro was strikingly similar to the original SSLOW diseases phenotype with respect to the incubation
time to disease, as well as clinical, neuropathological and biochemical features. Infrared microspectroscopy (IR-MSP)
indicated that PrPSc produced in animals upon transmission of recombinant PrPSc is structurally similar if not
identical to the original SSLOW PrPSc. The current study is the first to demonstrate that rPrP can support replication
of brain-derived PrPSc while preserving its strain identity. In addition, the current work is the first to document that
successful propagation of a hamster strain could be achieved in vitro using hamster rPrP.
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Introduction
Prion diseases or transmissible spongiform encephalop-
athies represent a class of lethal, transmissible neurodegen-
erative disorders of humans and animals [53]. The key
event underlying prion diseases involves the conform-
ational change of the α-helical, native, cellular form of the
prion protein (PrPC) expressed by a host on a cell surface
into a self-replicating, β-sheet rich, transmissible form
(PrPSc) [52]. PrPC is posttranslationally modified with a
glycophosphatidylinositol (GPI) anchor and up to two
N-linked glycans; these modifications are carried over
upon conversion of PrPC into PrPSc [58, 59, 62]. Prions
spread between organisms or from cell to cell by recruiting
host-encoded PrPC and replicating their disease-specific
misfolded structures via a template-assisted mechanism
[14]. According to this mechanism, PrPSc template recruits
PrPC expressed by a host and converts them into a new
PrPSc with the folding pattern faithfully repeating that of
the PrPSc template [14]. While prions can propagate indef-
initely via serial passaging in wild type hosts or cultured
cells, generating infectious prions in vitro de novo from
recombinant PrP (rPrP) has been a challenge [5].
In the absence of cellular cofactors, rPrP readily adopts
self-propagating β-sheet rich states including amyloid
fibrils [7, 8]. While rPrP amyloid fibrils propagate well in
vitro [9], they display miniscule specific infectivity in ani-
mals, as they do not recruit PrPC effectively [15, 29, 39,
43]. When inoculated into wild type hosts, rPrP amyloid
fibrils initiate a process of synthetic strain evolution that
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eventually lead to emergence of authentic PrPSc and clin-
ical prion disease upon serial passaging [43–46]. Evolution
of synthetic strains in vivo involves a transformation from
the PrP folding patterns specific to rPrP amyloid fibrils,
which do not accommodate well PrP with posttransla-
tional modifications, to the folding pattern specific to
PrPSc that can effectively recruit PrPC with GPI anchor
and N-linked glycans [42].
In the past decade, several studies demonstrated that
authentic PrPSc infectious to wild type host could be
generated using rPrP in vitro with assistance of cofactors
of polyanionic nature and/or lipids using serial protein
misfolding cyclic amplification (sPMCA) [21, 22, 63, 67].
Ma and colleagues showed that mouse recombinant
PrPSc, infectious to wild type mice, could be produced in
sPMCA de novo using rPrP in the presence of the an-
ionic phospholipid 1-palmitoyl-2-oleolyl-sn-glycero-3-
phospho(1′-rac-glycerol) and total liver RNA [63, 67].
Supattapone and colleagues showed that phosphatidyl-
ethanolamine (PE) can be used as a sole cofactor for
generating recombinant mouse PrPSc with high infectivity
titers in sPMCA reactions seeded with mouse prion strains
[21, 22]. Castilla and colleagues reported generation of
several new strains in bank voles upon transmission of
sPMCA-derived materials produced with assistance of
several cofactors of polyanionic nature and bank vole rPrP
as a substrate [23]. These studies established that highly
infectious recombinant PrPSc could be generated from rPrP
mixed with non-PrP components. In addition, these studies
provided illustration that presence of different cofactors
gave rise to different synthetic prion strains. However, it still
remains unclear whether strain-specific features could be
imposed on rPrP by brain-derived PrPSc seeds and, if so,
can be faithfully replicated by rPrP, i.e. whether prion strain
identity can be preserved by rPrP [60].
It has been well established that molecular features
responsible for prion strain identity are well preserved
when crude brain homogenates containing PrPC is used
for replicating prion strains in sPMCA [12, 28]. How-
ever, this is not the case, when rPrP is used for in vitro
conversion. Studies using quaking-induced conversion
assay revealed lack of infectivity and strain identity in
rPrP conversion products generated by seeding of rPrP
with a diverse range of prion strains originating from a
number of species [65]. Surprisingly, supplementing PE
as a sole cofactor to mouse rPrP conversion assays
restored high titer of prion infectivity, yet did not pre-
serve strain identity [22]. In fact, seeding of rPrP and PE
mixtures with three mouse strains gave rise to recom-
binant PrPSc that produced a new strain in wild type
mice with the same diseases phenotype regardless of the
original strain used for the seeding [22]. Moreover, simi-
lar results were obtained using hamster PrPC purified
from hamster brains as a substrate and synthetic polyA
as a sole cofactor [18]. Regardless of whether sPMCA
reactions mixtures consisting of purified hamster PrPC
and polyA were seeded with hamster strains Sc237 or
139H or conducted as non-seeded reactions, the newly
produced PrPSc gave rise to the same disease phenotype
in hamsters [18].
What are the minimal molecular requirements for a
faithful replication of a prion strain in vitro? Can faithful
replication of a prion strain be achieved using rPrP that
lacks posttranslational modifications? What is the min-
imal set of cofactors sufficient for a faithful replication
of a prion strain in vitro? Do prions from different
species rely on different sets of cofactors? The current
study reports that faithful replication of hamster strain
SSLOW could be achieved in vitro using rPrP as a
substrate. We found that a mixture of PE and polyA was
sufficient for stable replication of hamster brain-derived
SSLOW PrPSc in sPMCA that use hamster rPrP as a
substrate. The disease phenotype generated in hamsters
upon transmission of recombinant PrPSc produced in
vitro was strikingly similar to the original SSLOW
diseases phenotype with respect to the incubation time
to disease, clinical, neuropathological, biochemical and
structural features of PrPSc, as indicated by infrared
microspectroscopy. The current study is the first to
demonstrate that rPrP can support replication of
brain-derived PrPSc while preserving its strain identity.
Materials and methods
Brain material
Hyper and Drowsy scrapie brain materials were kindly
provided by Richard Bessen (Colorado State University,
Fort Collins, CO); 263K was kindly provided by Robert
Rohwer (Veterans Affair Maryland Health Care System,
Baltimore, MD); one 263K scrapie hamster brain used
for preparation and FT-IR analysis of highly purified
PrPSc was taken from the prion tissue archive at the
Robert Koch-Institute; SSLOW scrapie brain homogen-
ate was prepared using animals from the 4th passage of
SSLOW [45]; atypical PrPres was generated from brain
material in vitro as described [49]. Ten percent (wt/vol)
brain homogenates (10% BH) were prepared in PBS,
pH 7.4, using glass/Teflon homogenizers attached to a
cordless 12 V compact drill (Ryobi) as previously
described [45]. To seed PMCA, 10% BH was diluted in
PMCA conversion buffer [44] and briefly sonicated
immediately before use.
Expression and purification of rPrP
Syrian hamster full-length rPrP encompassing residues
23–231 was expressed and purified according to a previ-
ously described procedure [9] with minor modifications
[43]. Immediately before use, lyophilized rPrP was
dissolved in 10 mM Na acetate, pH 5.0, filtered through
Makarava et al. Acta Neuropathologica Communications  (2018) 6:92 Page 2 of 14
0.45 μm syringe filter and the rPrP concentration was
measured. For the formation of rPrPresPolyA, lyophilized
rPrP was dissolved in 5 mM MES, pH 6.0.
Cofactors
L-α-phosphatidylethanolamine (PE) from porcine brain
(#840022C, Avanti Polar Lipids, Alabaster, AL) was
supplied as 25 mg/ml stock in chloroform. Immediately
before use, an aliquot of PE was lyophilized in a glass
tube under a stream of compressed nitrogen, and then
re-suspended at 10 mM in 0.05% Triton-X by sonication
in a water bath until clear. PolyA (#P9403, Sigma) was
dissolved at 5 mg/ml in 10 mM Tris, pH 8.0, 1 mM
EDTA buffer, and stored frozen in aliquots.
Protein misfolding cyclic amplification (PMCA)
QSonica S-3000, S-4000 or Q700 sonicators (Newtown,
CT) equipped with a microplate horn were used for
PMCA reactions. Samples in 0.2 ml thin-wall PCR tubes
(Fisher #14230205) were placed in a floating rack inside
the horn filled with 300 ml water and covered with foil.
To maintain 37 °C temperature, two coils of rubber tub-
ing attached to a circulating water bath were installed
inside the horn. Alternatively, the horn and its enclosure
were put inside 37 °C incubator.
rPrPresPE was produced in 20 mM Tris, pH 7.5,
135 mM NaCl, 5 mM EDTA and 0.15% Triton X-100
supplemented with 5 μg/ml rPrP and 2.5 mM PE. For
the first round of PMCA, 90 μl aliquots of reaction
mixture were supplemented with 10 μl of diluted scrapie
brain homogenates as indicated (see Brain Material).
PMCA sonication program consisted of 5 s sonication
pulses at 150–200 W applied every 10 min during a 24 h
period. For each subsequent round, 30 μl of the reaction
from the previous round were added to 60 μl of fresh
substrate. Each PMCA reaction was carried out in the
presence of two 3/32” Teflon beads (McMaster-Carr).
To analyze production of PK-resistant PrP material in
PMCA, the samples were digested with 10 μg/ml PK at
37 °C for 1 h. The digestion was terminated by addition
of SDS-sample buffer and heating the samples for
10 min in a boiling water bath.
rPrPresPE + PolyA was produced in the presence of
2.5 mM PE and 20 μg/ml polyA using the same condi-
tions as for the reactions with PE as a sole cofactor,
except the Teflon beads were omitted, and for each sub-
sequent round, 20 μl of the reaction mixture from the
previous rounds were added to 80 μl of fresh substrate.
The ingredients were mixed in the following order. A
master mix consistent of water, Tris, NaCl, EDTA and
Triton X-100 was prepared first. Then rPrP was mixed
with PE and incubated for 10 min at room temperature.
After that, the polyA was added, followed by additional
5 min incubation. Finally, the master mix and rPrP mix
were combined and aliquoted. The 90 μl aliquots for the
first round were supplemented with 10 μl of seeds and
subjected to sonication immediately. The 80 μl aliquots
for the subsequent rounds were frozen at − 20 °C. Com-
pleted rounds were used to seed the following rounds on
the same day. The leftovers were kept frozen before the
subsequent analysis. PK-digestion was performed with
10 μg/ml PK at 37 °C for 1 h and terminated by addition
of SDS-sample buffer and heating the samples for
10 min in a boiling water bath.
To establish amplification efficiency in a standard
PMCA, 10% normal brain homogenate (NBH) from
healthy hamsters was prepared as described previously [44]
and used as a substrate [26]. To produce desialylated sub-
strate (dsNBH), 10% NBH was treated with Arthrobacter
ureafaciens sialidase (cat # N3786, Sigma-Aldrich, St.
Louis, MO) as described before [33]. For the first round,
90 μl of NBH or dsNBH were supplemented with 10 μl of
scrapie brain homogenates serially diluted in PBS. The
standard sonication program consisted of 20 s sonication
pulses at 150–200 W applied every 20 min during a 24 h
period. For each subsequent round, 10 μl of the reaction
mixtures from the previous round were added to 90 μl of
fresh substrate. Each PMCA reaction was carried out in
the presence of two 3/32” Teflon beads (McMaster-Carr).
To analyze production of PK-resistant PrP material in
PMCA, 10 μl of sample were supplemented with 5 μl of
SDS and 5 μl of PK to a final concentration of SDS and PK
of 0.25% and 50 μg/ml, respectively, followed by incubation
at 37 °C for 1 h. The digestion was terminated by addition
of SDS-sample buffer and heating the samples for 10 min
in a boiling water bath.
Formation of PrPresPolyA was achieved by serial PMCA
of 5 μg/ml rPrP in the buffer conditions similar to previ-
ously described [18]: 20 mM MOPS, pH 7.5, 150 mM
NaCl, 500 mM Imidasole, 0.5% Triton X-100, 50 mM
EDTA with the addition of 20 μg/ml PolyA. No seeds
were added to these reactions. PMCA sonication pro-
gram consisted of 30 s sonication pulses at 150–200 W
applied every 30 min during a 24 h period. For each sub-
sequent round, 10 μl of the reaction from the previous
round were added to 90 μl of fresh substrate. To analyze
production of PK-resistant PrP material in PMCA, the
samples were digested with 20 μg/ml PK at 37 °C for
1 h. For PK-digestion pattern comparison, R-fibrils (F2M)
produced from rPrP as described previously [41] were
digested with 1:5000 PK:rPrP ratio at 37 °C for 1 h. The
digestion of all samples was terminated by addition of
SDS-sample buffer and heating the samples for 10 min
in a boiling water bath.
Bioassay
Each animal received 50 μl (S. hamsters) or 20 ul (Tg7
mice) of inoculum intracerebrally, under 2% O2/4
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minimum alveolar concentration (MAC) isoflurane
anesthesia. After inoculation, animals were observed daily
for disease using a ‘blind’ scoring protocol. Non-habituating
startle response to sound and/or touch was considered the
first clinical sign and was marked as an onset of the disease
when consistently observed during consecutive scoring
sessions. The animals were euthanized at a terminal stage
when unable to rear and having troubles to right them-
selves after flipping to their backs.
PrPSc detection by Western blot
An aliquot of 10% BH was mixed with an equal volume
of 4% sarcosyl in PBS, supplemented with 50 mM Tris,
pH 7.5, and digested with 20 μg/ml PK (New England
BioLabs) for 30 min at 37 °C with 1000 rpm shaking
using a DELFIA plate shaker (Wallac) placed in 37 °C
incubator. PK digestion was stopped by adding SDS
sample buffer and heating the samples for 10 min in a
boiling water bath. Samples were loaded onto NuPAGE
12% Bis-Tris gels, transferred to PVDF membrane, and
probed with 3F4 or SAF-84 antibody [45].
Analysis of conformational stability and proteinase K
resistance
Ten percent brain homogenate was diluted 10 times into
PMCA conversion buffer, then supplemented with an
equal volume of GdnHCl solution in PBS to a final
concentration of GdnHCl ranging from 0.4 to 4 M and in-
cubated at room temperature for 1 h. Next, nine volumes
of 2% sarkosyl in PBS were added to all samples followed
by 1 h incubation at room temperature, and then the sam-
ples were treated with 20 μg/mL PK for 1 h at 37 °C with
shaking. The digestion was stopped with 2 mM PMSF,
and the proteins were precipitated in four volumes of
ice-cold acetone, incubated overnight at − 20 °C, and sub-
sequently centrifuged for 30 min at 16000 x g. Pellets were
dried for 30 min, resuspended in 1 × SDS-sample buffer,
loaded into NuPAGE 12% bisTris gels, then transferred to
PVDF membrane, and stained with 3F4 antibody.
Histopathological study
Histopathological studies were performed on three ani-
mals per group. Formalin fixed brain halves were divided
at the midline. Right hemisphere was frozen, and left
hemisphere was fixed in 10% neutral buffered formalin
solution. Brains were treated for 1 h with 96% formic
acid prior to embedding in paraffin to deactivate prion
infectivity. Paraffin embedded brains were sliced into
4 μm sections and processed for hematoxylin-eosin stain
as well as for immunohistochemistry for PrP using the
mouse monoclonal anti-PrP antibody 3F4 (1:1000,
Covance, Berkeley, CA, USA), or rabbit anti-glial fibril-
lary acidic protein (GFAP; 1:500, Novus, Littleton, CO,
USA), or rabbit anti-ionized calcium-binding adapter
molecule 1 (Iba1; 1:500, Wako, Richmond, VA, USA).
Horse radish peroxidase-labeled goat anti-mouse and
anti-rabbit antibody (KPL, Milford, MA) were used as
secondary antibody. For detection of disease-associated
PrP, we applied a pretreatment of 30 min hydrated auto-
claving at 121 °C followed by 5 min in 96% formic acid.
Detection was performed using DAB Quanto chromogen
and substrate (VWR, Radnor, PA).
Procedure for purification of scrapie material
Extraction of PrPSc (in the form of PrP27–30) from a
263K scrapie hamster and from three hamsters (i, ii, and
iii) from the second passage of SSLOWPE + PolyA for
FTIR microspectroscopic analysis was performed as
described by Daus et al. [16] with the following modifi-
cations: hemispheres of mid-saggitally split hamster
brains (approximately 0.5 g) were each homogenized in
adjusted volumes of homogenization buffer for the prep-
aration of 10% (w/v) brain tissue homogenates. From
each donor animal, two aliquots of 1 mL of 10% (w/v)
brain tissue homogenate were subjected to the extrac-
tion procedure. This yielded two final pellets of highly
purified PrPSc per donor animal, each corresponding to
0.1 g of brain tissue. For infrared spectroscopic analysis
final PrPSc pellets were washed in double-distilled water
as described [16] and resuspended in 10 μL of double-
distilled H2O. 1 μL aliquots of these PrP
Sc suspensions
were transferred for drying onto a CaF2 window of 1 mm
thickness (Korth Kristalle GmbH, Altenförde, Germany).
Infrared microspectroscopy (IR-MSP)
IR-MSP analysis of highly purified PrPSc extracts were
carried out as previously described [16]. Briefly, mid-IR
spectra were acquired in transmission mode using an
IFS 28/B FT-IR spectrometer from Bruker (Bruker
Optics GmbH, Ettlingen Germany) that was linked to an
IRscope II infrared microscope (Bruker). IR microspectra
were recorded with a spatial resolution of approximately
80 μm. Nominal spectral resolution was 4 cm− 1, and the
zero filling factor was 4. For each background and for
each sample spectrum, 512 individual interferograms
were averaged, zero-filled and apodized using a
Blackman-Harris 3-term apodization function. For each
examined PrPSc extract from one 263K scrapie hamster
and from hamsters i, ii, and iii infrared spectra were
recorded at three different positions in PrPSc sample
spots dried on CaF2 windows. Data acquisition and spec-
tral preprocessing was carried out by utilizing Bruker’s
instrument software OPUS v. 5.5. Second derivative
spectra were obtained by means of a 9-smoothing point
Savitzki-Golay derivative filter. Spectra from the 263K
scrapie hamster and the three hamsters i, ii, and iii were
vector normalized in the wave number region between
1610 and 1700 cm− 1.
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Results
PolyA as a sole cofactor is not sufficient for assisting
conversion of hamster rPrP into PrPSc
Previous studies revealed that RNA molecules including
synthetic, homopolymeric nucleic acids such as polyA
assisted conversion of PrPC into self-propagating, PK-re-
sistant, PrPSc-like states in sPMCA [17, 20]. Moreover,
RNAs were found to facilitate conversion of hamster
PrPC, but not mouse or vole PrPC, into PrPSc [19]. These
results emphasized species-specific differences in bio-
chemical environment important for conversion. Taking
previous data into consideration, we decided to test
whether PolyA is sufficient for assisting conversion of
hamster rPrP into authentic PrPSc in vitro. To answer
this question, non-seeded sPMCA reactions that utilized
hamster rPrP as a substrate were carried out in the pres-
ence or absence of synthetic polyA. In the presence of
polyA, PK-resistant products appeared between 3rd and
5th sPMCA round, whereas no products were detected
in the reactions conducted in the absence of polyA
(Additional file 1: Figure S1A). The PMCA-derived,
PK-resistant products (rPrPresPolyA) consisted of expected
peptide of ~ 16 kDa and two shorter peptides of 10 kDa
and 8 kDa, which were all detectable by SAF-84 antibody.
Once formed, rPrPresPolyA was able to propagate in
sPMCA with rPrP as a substrate, albeit with some varia-
tions in yield (Additional file 1: Figure S1A).
For testing whether rPrPresPolyA is infections, Syrian
hamsters and transgenic mice that overexpress hamster
PrPC on an ablated background (tg7) were inoculated
with PMCA-derived rPrPresPolyA material. Hamsters did
not develop any clinical signs of the disease and were
euthanized at 661 days postinoculation. No PK-resistant
material was found in brains of hamsters by Western
blots (Additional file 1: Figure S1B). Despite expression
of PrPC at a level of 3.5-fold higher than that in a ham-
ster [34], tg7 mice did not develop any clinical signs of
the disease for up to 524 days postinoculation and were
euthanized. However, Western blot analysis of tg7 mice
revealed PK-resistant products that were detectable by
SAF-84 and consisted of three bands with molecular
weight of 23, 16 and 10 kDa. Such PK-digested pattern
suggests that upon inoculation of rPrPresPolyA, tg7 mice
produced PrPres state different from authentic PrPSc,
but similar to the atypical PrPres described in our previ-
ous studies [44, 46, 48, 49]. Serial transmission of
rPrPresPolyA in tg7 mice displayed dynamics similar to
those previously observed for the serial transmission of
atypical PrPres [44, 46, 48, 49]. In a 2nd passage, tg7
mice did not develop clinical disease, yet again three
PK-resistant bands of 23, 16 and 10 kDa were observed
using SAF-84 antibody (Additional file 1: Figure S1B)
documenting a self-replicating nature of this state. In
addition, small amounts of PrPSc were detectable by
SAF-84 and 3F4 antibodies (Additional file 1: Figure
S1B). In summary, animals inoculated with rPrPresPolyA
material did not develop clinical disease nor did they
produce PrPSc in a first passage arguing that rPrPresPolyA
preparation does not contain authentic PrPSc.
Both PE and polyA are required for efficient conversion of
hamster rPrP into PrPSc in vitro
While the experiments on polyA had been carried out,
cellular lipids and, specifically, PE were shown to be
essential for converting rPrP into infectious PrPSc in
vitro, albeit with a loss of strain identity [21, 22, 63, 64].
Therefore, next we assessed the effect of PE on
converting hamster rPrP. sPMCA reactions with rPrP as
a substrate were seeded by hamster strains Hyper (HY),
Drowsy (DY) or synthetic strain SSLOW. Small amounts
of PK-resistant product (referred to as rPrPresPE) with
molecular weight ~ 16 kDa, expected for recombinant
PrPSc, were detected in reactions seeded with SSLOW,
but not with HY, DY or non-seeded reactions (Fig. 1a).
For testing whether PE also facilitates alternative
misfolding pathway leading to atypical PrPres, sPMCA
reactions were seeded with brain-derived atypical PrPres,
yet no PK-resistant bands were observed (Fig. 1a). Among
the strains used for seeding, only reactions seeded with
SSLOW showed positive results in the presence of PE
(Additional file 1: Figure S2). It is unlikely that this differ-
ence could be attributed to the strain-specific differences
in the efficiency of amplification in sPMCA, because HY
was found to display significantly higher amplification
efficiency than SSLOW in conventional sPMCA [24, 27].
Nevertheless, in the presence of PE alone, SSLOW-seeded
rPrPresPE propagated with low efficiency and only at low
dilution factor between serial PMCA rounds. Next, we
tested whether supplementing both polyA and PE will
improve the yield and the efficiency of amplification. Serial
PMCA reactions were seeded with brain-derived SSLOW
or PMCA-derived rPrPresPE and conducted in the pres-
ence of a mixture of PE and polyA or PE alone. In both
rPrPresPE- and SSLOW-seeded reactions, stable amplifica-
tion of the 16 kDa PK-resistant product was observed only
in the presence of a mixture of PE and polyA (will be
referred to as rPrPresPE + PolyA), but not PE alone (Fig. 1b,
c). rPrPresPE + PolyA could be detected by 3F4 antibodies,
arguing that the central PrP region that is missing in
atypical PrPres was present in rPrPresPE + PolyA. No lower
molecular weight bands characteristic for atypical PrPres
were detected in PK-digested rPrPresPE + PolyA upon
immunoblotting with SAF-84 antibody, suggesting that
rPrPresPE+ PolyA conformation is different from rPrPresPolyA.
rPrPresPE + PolyA is transmissible
To test whether rPrPresPE + PolyA is infectious, sPMCA
reaction with hamster rPrP was seeded by 103-diluted
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SSLOW brain material, subjected to 18 rounds of
sPMCA (Fig. 1c), then ten-fold diluted sPMCA-derived
products were inoculated in Syrian hamsters. The final
inoculum contained 1.3 × 1016-fold diluted SSLOW
brain material; this dilution is approximately 107-fold
higher than the limiting dilution of SSLOW as deter-
mined by bioassay [47]. Three out of four hamsters
inoculated with rPrPresPE + PolyA developed first clinical
signs of disease by 517 days postinoculation showing
non-habituating startle response to sound and an agi-
tated, fidgeting behavior. With disease progression, three
animals with clinical signs showed increasing difficulty
righting themselves when rolled onto their back. Their
hair became dry and detached in clumps. Three clinical
animals were euthanized along with one non-clinical
animal at 622 days postinoculation (Table 1). All four
animals showed PrPSc on Western blots detectable by
3F4 and SAF-84 with the lowest amount observed in the
sub-clinical animal (Fig. 2a). In three clinical animals the
amounts of PrPSc were similar to those in terminal
SSLOW-inoculated animals (Fig. 2a). Histopathological
analysis of sick animals revealed accumulation of PrPSc
in forms of diffused synaptic deposits or small aggregates
in multiple brain regions including subpial areas, deep
layers of cortex, thalamus, hippocampus, cerebellum and
subventricular regions (Fig. 3). Notably, hippocampus
showed intense deposition of PrPSc in the stratum-lacuno-
sum region (Fig. 3f, h), a pattern of deposition reminiscent
of SSLOW [30, 43, 45]. Hematoxylin and eosine staining
revealed moderate vacuolation in several brain areas in-
cluding thalamus (Fig. 3d). PrPSc material from animals
inoculated with rPrPresPE + PolyA will be referred to as
SSLOWPE+ PolyA.
For examining strain-specific biochemical properties of
SSLOWPE+PolyA, we analyzed amplification efficiency of
brain-derived PrPSc using normal PMCA and dsPMCA, in
Fig. 1 Attempts to produce Ha-rPrPSc with assistance of PE and
PolyA. a Duplicate sPMCA reactions were seeded with 103-fold
diluted brain-derived Hyper (HY), Drowsy (DY) or SSLOW, or atypical
PrPres produced in vitro, then subjected to four sPMCA rounds in
the presence of PE with 3-fold dilutions between rounds and
analyzed by Western blot. Products of 4th sPMCA rounds are shown.
Small amounts of PK-resistant material (rPrPresPE) were detected in
the reactions seeded with SSLOW (indicated by arrow). b sPMCA
reactions were seeded with PMCA-derived rPrPresPE or 103-fold
diluted SSLOW brain material, then subjected to four serial rounds in
the presence of PE alone or a mixture of PE and polyA with 5-fold
dilutions between rounds and analyzed by Western blots. c Serial
amplification of rPrPresPE + PolyA in PMCA. sPMCA reactions were
seeded with 103-fold diluted SSLOW brain material, then subjected
to 18 serial rounds in the presence of PE and polyA with 5-fold
dilutions between rounds and analyzed by Western blots. SAF-84
antibody was used to verify the absence of low molecular weight
bands upon PK-digestion (middle panel)
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which desialylated substrate is used. Our previous studies
revealed that desialylation of PrPC increases the amplifica-
tion rate in a strain-specific manner. For instance, in
dsPMCA the amplification rate of SSLOW PrPSc increased
by several orders of magnitudes relative to its amplification
rate in PMCA [33]. PMCA and dsPMCA reactions were
seeded with serially-diluted brain-derived SSLOWPE+PolyA,
SSLOW or 263K and amplified in one round. The amplifi-
cation rate of 263K increased only by 10-fold in dsPMCA
relative to that of PMCA, whereas the amplification rates of
SSLOWPE+PolyA and SSLOW increased by approximately
103–104 folds. This experiment illustrates that SSLOWPE+
PolyA material has amplification dynamics similar to that of
SSLOW.




b inc time c, dpi duration d, days
1st 3/4 4/4 517 105
2nd e 6/6 6/6 274, 4 at 300, 324 110, 122, 126, 133, 134, 160
2nd e 5/5 5/5 274, 2 at 288, 324, 335 105, 116, 119, 146, 166
a The number of animals that developed clinical signs per total number of animals
b The number of animals with PrPSc on Western blot per total number of animals
c Incubation time to first clinical signs
d Duration of clinical disease from the first clinical signs to the terminal stage
e For the second passage, two inocula were prepared using two individual animals from the first passage
Fig. 2 Serial transmission and characterization of the strain produced upon inoculation of rPrPresPE + PolyA. a Western blots of brain materials from
animals inoculated with PMCA-derived rPrPresPE + PolyA and sacrificed at 622 days post-inoculation. One and ten percent brain homogenates from
SSLOW-inoculated animals are provided as a reference. b Comparison of amplification efficiency of PrPSc in PMCA and dsPMCA that utilizes
desialylated substrate. PMCA or dsPMCA reactions were seeded with SSLOWPE + PolyA, SSLOW or 263K brain materials serially diluted to up to 1010-
fold as indicated, subjected to one amplification round and analyzed by Western blot. In a manner similar to SSLOW, amplification efficiency of
SSLOWPE + PolyA increased drastically in dsPMCA conditions relative to that of PMCA conditions. c Western blots of brain materials of the first and
second passages of SSLOWPE + PolyA. Arrows indicate animals that were used for the serial transmission. 3F4 antibody was used. d Kaplan-Meier
survival curves for animals inoculated with SSLOW (circles) or SSLOWPE + PolyA (2nd passage, two individual groups, squares and triangles)
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For assessing transmissibility of SSLOWPE + PolyA, 10%
SSLOWPE + PolyA brain homogenates from two animals
were inoculated into two new hamster groups. Animals
of both groups developed first clinical signs of the dis-
ease between 274 and 335 days postinoculation (Table 1).
The clinical disease progressed slowly and all animals
approached terminal stage by 420–440 days postinocula-
tion (Table 1, Fig. 2c, d). For the second passage of
SSLOWPE + Poly, the incubation time to the first clinical
signs, the duration of the clinical diseases, the timing of
terminal stage of the disease and set of clinical signs
were highly reminiscent to SSLOW (Fig. 2d) [45].
Non-habituating startle response to sound and touch
and an agitated, fidgeting behavior were the first signs of
the disease. As the disease progressed the animals had
increasing difficulty righting themselves when rolled
onto their back. The hair became dry and detached in
clumps. Most animals appeared overweight, pear shaped
with enlarged abdomens and hind quarters. At the time
of euthanasia the animals had become less active and
unable to rear. Histopathological examination revealed
strong PrPSc deposition in multiple brain areas including
deep layers of cortex, thalamus, hippocampus and cere-
bellum (Fig. 4a, e, f, g). Similar to SSLOW, SSLOWPE +
Poly was characterized by strong perivascular deposition
of PrPSc (Fig. 4g). Vacuolation and neuroinflammation of
microglia and astrocytes were observed throughout the
brain, but particularly strong in the areas of intense
PrPSc accumulation (Fig. 4b, c, d).
SSLOWPE + PolyA displays SSLOW-specific structural and
neuropathological features
The question of considerable interest is whether propaga-
tion of SSLOW in vitro with an assistance of PE and
polyA preserved strain-specific disease phenotype. For ad-
dressing this question, first we examined patterns of PrPSc
deposition peculiar to SSLOW. SSLOW is characterized
by intense accumulation of diffuse PrPSc in the stratum
lacunosum-moleculare of the hippocampus, which is
accompanied by a marked astrocytic inflammation in the
same area [30]. Analysis of SSLOWPE+ Poly revealed
intense deposition of PrPSc and astrocytic gliosis in
stratum lacunosum-moleculare typical for SSLOW
(Fig. 4a, d). In a manner similar to SSLOW, SSLOWPE+
Poly-infected animals also displayed other SSLOW-specific
neuropathological features including diffuse PrPSc in
deeper layers of cortex, intense narrow PrPSc staining in
subpial area and PrPSc plaques in subependymal areas
(Fig. 5a-g). Overall, the region-specific intensity of PrPSc
deposition was very similar in animals infected with
SSLOWPE+ Poly and SSLOW, where thalamus and sube-
pendymal areas displaying the strongest deposition, and
cerebellum the weakest (Figs. 4 and 5) [43, 45].
Second, PrPSc was purified in the form of PrP27–30
from SSLOWPE + Poly-infected animals and its structural
features were examined using infrared microspectro-
scopy (Fig. 6). Infrared spectroscopy and microspectro-
scopy have been established as a powerful analytical tool
for the detection of structural differences between PrPSc
from various native prion strains or PMCA parent and
progeny seeds [13, 16, 31, 55, 61]. SSLOWPE + Poly and
SSLOW showed very similar if not identical IR spectra
that were characterized by a major peak at 1626–1627
cm− 1 that indicates the presence of β-sheet secondary
structure elements, a small peak at 1696 cm− 1 that also
reports on β-sheet structures and a moderate peak at
1658–1659 cm− 1 which is typically assigned to an
α-helical conformation and/or disordered structures [3, 4]
(Fig. 6a, b). The shape of IR spectra displayed by
SSLOWPE+ Poly and SSLOW was markedly different from
that of 263K (Fig. 6c) [16, 57].
Third, we examined conformational stability of PrPSc in
GdnHCl-induced denaturation experiment. The
Fig. 3 Histopathological analysis of animals from the first passage of
rPrPresPE + PolyA. PrPSc was found in form of diffused synaptic
deposition and small aggregates in subpial areas (a), deep layers of
cortex (b), thalamus (c), cerebellum (e), hippocampus (f), and
subventricular regions (g). Stratum-lacunosum (s-l) of hippocampus
has characteristically intense deposition of PrPSc (f, h) with a pattern
reminiscent of SSLOW [30, 43, 45]. Hematoxylin and eosine staining
revealed moderate vacuolation in several brain areas including
thalamus (d). Scale bars = 200 μm (a-d, g, h) or 300 μm (e, f)
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conformational stability was found to be similar for four
groups examined: SSLOWPE+Poly from the 1st and 2nd
passages, SSLOW and 263K (Additional file 1: Figure S3A).
This result is consistent with the previous study that docu-
mented similar stability of SSLOW and 263K [43]. How-
ever, the band pattern was different between 263K and the
three members of SSLOW group (SSLOWPE+Poly from the
1st and 2nd passages, SSLOW) (Additional file 1: Figure
S3A). Because electrophoretic mobility of PK is similar to
the band corresponding to diglycosylated PrP isoform, the
area on the membrane where PK is present has reduced
binding of anti-prion antibody, which creates a blind
spot. Since PK-related blind sport serves as an internal
reference for each lane of SDS-PAGE, this approach
was found to be reliable for comparing minor differ-
ences between electrophoretic mobility of prion strains,
as documented in our previous studies [32]. We found
that the PK-related blind spot hides the upper half of
diglycosylated PrP band for SSLOW group, while it cuts
though the middle of the band for 263K, illustrating
slightly higher electrophoretic mobility of the members
of SSLOW group relative to that of 263K (Add-
itional file 1: Figure S3A). Direct comparison of electro-
phoretic mobility confirmed that SSLOWPE + Poly and
SSLOW displayed slightly higher mobility in compari-
son to 263K (Additional file 1: Figure S3B).
Discussion
In the recent decade, enormous progress has been made in
generating highly infectious prions in vitro using rPrP as a
substrate. Several experimental protocols for converting
rPrP into PrPSc have been developed that highlight import-
ance of lipids and/or polyanionic molecules for assisting
rPrP conversion in vitro [21–23, 35, 63, 67]. These studies
established that rPrP that lacks posttranslational modifica-
tion is able to support replication of highly infectious PrPSc,
yet it remains unclear whether prion replication in rPrP can
preserve strain identity. In previous studies, seeding of rPrP
by brain-derived PrPSc gave rise to new prion strains with
new disease phenotypes documenting loss of a strain iden-
tity upon replication in rPrP substrate [21–23, 35]. Remark-
ably, loss of prion strain identity upon replication in rPrP
was mirrored by the studies conducted in transgenic mice
with deficient posttranslational modifications of PrPC [1,
40]. Transmission of mouse-adapted prion strain RML or
mCWD to transgenic mice expressing PrPC devoid of GPI
anchor and deficient in N-linked glycosylation led to
formation of novel prion strains, which maintained
their novel properties upon transmission to wild type
mice [1, 40]. In a similar fashion, passaging of prion
strains through transgenic mice expressing PrPC devoid
of just N-linked glycans resulted in changes of
strain-specific infectious properties upon passaging
back to wild type host [11].
In the current study, replication of hamster strain
SSLOW was achieved in vitro using rPrP as a substrate
with assistance of the mixture of polyA and PE. The
disease phenotype generated upon transmission of
rPrPresPE + PolyA in hamsters was strikingly similar to the
original SSLOW diseases phenotype. In the second
Fig. 4 Histopathological analysis of animals from the second passage of rPrPresPE + PolyA. PrPSc deposition in hippocampus (a), deep layers of
cortex (e), thalamus (f), and cerebellum (g) as shown by 3F4 staining. Vacuolation and reactive gliosis were observed in the areas of PrPSc
accumulation, as shown for hippocampus using staining with hematoxylin and eosine (c), or staining of microglia with anti-Iba1 (b) or astrocytes
with anti-GFAP (d). Scale bars = 300 μm (a-d) or 200 μm (e-g)
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passage of SSLOWPE+ Poly, the incubation time to the first
clinical signs, the duration of the disease progression, the
incubation time to terminal stage and the set of clinical
signs were highly reminiscent to the characteristics of
prion infection by SSLOW (Fig. 2d). Moreover, neuro-
pathological analysis demonstrated remarkable
resemblance between animals affected by SSLOWPE+ Poly
and those affected by SSLOW with respect to brain
regions affected by PrPSc and PrPSc deposition patterns
(Figs. 4 and 5). Analysis of purified PrPSc using infrared
microspectroscopy indicated that SSLOWPE+ PolyA and
SSLOW had very similar, if not identical, secondary struc-
tures (Fig. 6). IR-MSP is very sensitive technique which
can be used to detect even very small structural changes
[13, 16, 31, 55, 61]. While the fact that we cannot detect
any spectroscopic differences does not fundamentally ex-
clude conformational differences, yet our IR-MSP results
indicate that conformational differences, if there are any,
must be very small. In addition to similar secondary struc-
tures, SSLOWPE+ PolyA and SSLOW PrPSc showed very
similar amplification dynamics in PMCAs that employed
normal and desialylated substrate (Fig. 2b). Finally,
SSLOWPE+ PolyA and SSLOW PrPSc displayed similar elec-
trophoretic mobility, which was slightly faster in compari-
son to that of 263K (Additional file 1: Figure S3). The
current study is the first to demonstrate the proof of
principle that rPrP is capable of preserving strain identity
of brain-derived PrPSc.
In previous studies, the majority of work on generating
infectious recombinant prions has been conducted using
mouse rPrP [21, 22, 63, 67]. The current study is the
first to document that successful propagation of a ham-
ster strain could be achieved in vitro using hamster rPrP.
Propagating of hamster strains in vitro using rPrP or
unglycosylated PrPC was found to be very challenging.
All hamster strains, whether of natural or synthetic
origin, are predominantly diglycosylated [2, 27]. In fact,
previous studies showed that diglycosylated PrPC mole-
cules were required for propagating hamster Sc237 strain
in PMCA [50]. Surprisingly, while unglycosylated mouse
PrPC were required for replicating mouse prions, unglyco-
sylated hamster PrPC molecules inhibited replication of
hamster prions [50]. In vivo, N-linked glycans might
play a role in facilitating the assembly of hamster PrPSc
or stabilizing PrP molecules within hamster PrPSc [50].
The current work provides a proof of principle that
faithful replication of hamster prion strain that typically
relies on diglycosylated PrPC molecules could be
achieved in the absence of N-linked glycan, but with
assistance of two cofactors.
Fig. 5 Comparison of neuropathological features of SSLOWPE + PolyA and SSLOW. a, b Both SSLOWPE + PolyA and SSLOW shows similar patterns of
PrPSc accumulation in cortex including deposition in subpial area (black arrowhead), strong deposition in deeper layers of cortex (white
arrowhead), and plaques in subependymal areas (arrow). c Cortex of 263K-infected animals displays different pattern of PrPSc deposition (d – g).
Subependymal plaques (d, e) and subpial deposition of PrPSc (f, g) in SSLOWPE + PolyA (d, f) and SSLOW (f, g) animals. Scale bars = 300 μm (a-c) or
200 μm (d-g)
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It is not clear whether the results presented in the
current study represent a rare exception or general rule.
We do not know whether other hamster-adapted strains
might have more stringent requirements for propagation
using rPrP as a substrate including not only a different
set of cofactors, but also PMCA amplification conditions
(dilution between rounds, sonication time and power).
While failure of DY to utilize rPrP substrate in the
current study could be attributed to its very low rate of
replication, as assessed in conventional PMCA reactions
[2], this is not the case for HY. In fact, with PrPC as a
substrate the replication rate of HY was found to be fas-
ter than that of SSLOW [27]. One possibility behind
faithful replication of SSLOW in rPrP substrate could be
attributed to its synthetic origin, as it was generated via
serial transmission of rPrP amyloid fibril prepared in
vitro [43]. However, such possibility, should be
considered with great caution, because structure of rPrP
fibrils that gave rise to SSLOW were fundamentally
different from that of authentic PrPSc including SSLOW
PrPSc, which emerged in hamster upon serial passaging
[51, 66]. In fact, four serial passages in hamsters were re-
quired to stabilize SSLOW-specific disease phenotype
and PrPSc properties [42, 45, 48, 49]. While SSLOW is a
strain of synthetic origin, animals infected with SSLOW
display all key neuropathological and biochemical char-
acteristics of transmissible spongiform encephalopathies
including chronic neuroinflammation and neurodegener-
ation, spongiform vacuolation, deposition of bona fide
PrPSc, efficient transmission of the disease between
animals, high infectivity titer and efficient amplification
of SSLOW PrPSc in PMCA [30, 38, 45, 47]. In a manner
similar to PMCA amplification of hamster strains of
natural origin, amplification of SSLOW in PMCA dis-
played dependence on RNAs, the sialylation status of
N-linked glycans, and also showed a species barrier
upon amplification in mouse substrate [26, 27, 33].
Previous studies documented that RNA molecules
including polyA facilitate in vitro replication of hamster
Fig. 6 Comparison of the secondary structure of PrPSc materials by
infrared microspectroscopy. a Second derivative IR microspectra
obtained from PrPSc material purified in the form of PrP27–30 from
three individual SSLOW-infected hamsters (these spectral data
originate from the study [31]). b Second derivative IR microspectra
obtained from PrPSc material purified in the form of PrP27–30 from
three individual hamsters (i, ii, and iii) from the second passage of
SSLOWPE + PolyA. Technical replicate spectra were acquired for each
hamster at three different positions in PrPSc sample spots dried on
CaF2 windows. c Second derivative IR microspectra obtained from
PrPSc material purified in the form of PrP27–30 from one 263K
scrapie hamster brain. Technical replicate spectra were acquired at
three different positions in PrPSc sample spots dried on a CaF2
window. Similar spectra of highly purified PrPSc from 263K scrapie
hamster brain were previously published elsewhere [16, 57]
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prion strains in PMCAs that employ brain-derived ham-
ster PrPC as a substrate [18, 20]. Notably, the effect of
RNAs on stimulating prion replication was found to be
species- and strain-dependent [19, 27, 54]. RNAs had
strong stimulating effects on replication of hamster
strains, yet their effect on mouse strains was consider-
ably less pronounced and strain-dependent [19, 27, 54].
The current study demonstrated that polyA can facilitate
misfolding of hamster rPrP (Additional file 1: Figure S1).
However, in the presence of polyA as a sole cofactor,
rPrP misfolded into PK-resistant, self-replicating state,
which was different from PrPSc (Additional file 1: Figure
S1). These data suggest that polyA and, perhaps, other
RNAs indeed promote PrP misfolding, however without
imposing strict constraints with respect to misfolding
pathways. Interestingly, our previous studies demonstrated
that serial replication of hamster strain 263K in PMCA
conducted in RNA-depleted brain homogenates resulted
in self-replicating PrP states that failed to produce prion
disease in hamsters [25, 32] .
In previous studies, PE was found to be sufficient as a
sole cofactor for propagating mouse prion strains in vitro
and generating highly infectious recombinant PrPSc from
rPrP [21, 22]. In the present work, we were not able to effi-
ciently propagate SSLOW using rPrP as a substrate in the
presence of PE as a sole cofactor (Fig. 1b). The current
results are consistent with previous observations that repli-
cation of hamster strains exhibit stronger dependency on
polyanions than mouse strains [19]. Our work also suggests
that faithful replication of prion strains from different
species using rPrP might requires different sets of cofactors.
The current study demonstrates that rPrP can support
replication of brain-derived PrPSc preserving its stain
identity despite lack of posttranslational modifications. In
contrast to rPrP, PrPC that serves as a replication substrate
in a brain is posttranslationally modified with GPI anchor
and N-linked glycans [58, 59, 62]. Previously, we proposed
that in PrPC, posttranslational modifications might limit
the diversity of misfolding pathways that are otherwise ac-
cessible to rPrP [6, 10, 36]. Consistent with this view, pre-
vious studies documented changes in strain-specific
disease phenotype and physical properties of PrPSc upon
passaging of prion stains in transgenic mice expressing
PrPC devoid of GPI anchor and/or N-linked glycans [1,
11]. In the absence of posttranslational modifications and
cofactors, rPrP alone displays a broad spectrum of misfold-
ing pathways [7, 36, 41]. What is the mechanism behind
PE-assisted conversion of rPrP into PrPSc? Our previous
studies that employed steady-state spectroscopic tech-
niques failed to find any evidence of direct physical interac-
tions between PE and rPrP [56]. Bearing this in mind, one
could propose that interactions between PE and rPrP are
very weak and/or transient (PE-rPrP complexes exists for
very short time periods). If this is the case, only a tiny
fraction of rPrP could be found in a state bound to PE at
any given time, the fraction that could be presumably an
intermediate toward PrPSc. According to this mechanism,
PE could promote misfolding of rPrP directly, along the
pathway that leads to PrPSc. Alternatively, PE might assist
rPrP conversion into infectious states indirectly, i.e. by
binding and neutralizing intermediates toward alternative,
non-infectious amyloid states. This mechanism proposes
that PE might limit the diversity of misfolding pathways. If
this is the case, one would expect that PE would promote
replication of other hamster strains, which was not sup-
ported by current observations. A third possibility is that
PE is involved transiently at the stage of interaction of rPrP
with PrPSc seeds. Whether such transient interactions de-
pend on strain-specific properties of PrPSc seeds remains
to be established. Regardless of the specific mechanism, PE
was found to be essential for propagating SSLOW-specific
features using rPrP.
Incomplete attack rate and prolonged incubation time
to disease observed in the first passage of SSLOWPE+ PolyA
argues that sPMCA-derived rPrPresPE + PolyA material had
low specific prion infectivity (Table 1). A drop in specific
prion infectivity could be due to accumulation of alterna-
tive, non-infectious, self-replicating states that replicate
faster than SSLOW PrPSc in sPMCA with rPrP. In
addition, such drop could also be due to conformational
changes and/or changes in size of SSLOW PrPSc particles
during sPMCA. Notably, the diminished specific prion
infectivity in sPMCA is not specific to sPMCA that em-
ploys rPrP as a substrate, as it was previously documented
for conventional sPMCAs conducted with PrPC as a sub-
strate. In fact, previous studies established that replication
of hamster strains including 263K and SSLOW in sPMCA
reactions consisting of multiple rounds reduced prion in-
fectivity [31, 37]. In our previous study, hamsters inocu-
lated with sPMCA-derived SSLOW subjected to 24
rounds of PMCA in normal brain homogenates did not
develop clinical diseases for at least 621 days postinocula-
tion, but showed PrPSc accumulation in their brains and
spleens [31]. Nevertheless, the fact that SSLOWPE+ PolyA
animals from the 2nd passage showed incubation time to
diseases, disease phenotype and structural PrPSc features
typical for SSLOW argued that at least a fraction of
sPMCA-derived rPrPresPE + PolyA material preserved
authentic properties of SSLOW upon replication in rPrP.
Conclusions
The current study is the first to demonstrate that faithful
replication of a prion strain that preserves strain-specific
identity could be achieved in vitrousing recombinant
prion protein despite lack of posttranslational modifica-
tions. Faithful replication required two cofactors to be
present in the reaction mixture with recombinant prion
protein: poly A and phosphatidylethanolamine.
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